+205.3%
MNST vs MRNA
+561.6%
-356.3%
-27.6%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -0.6% | -2.2% | +1.6% | -0.5% |
| 7D | -6.5% | +5.5% | -12.0% | -6.6% |
| 30D | -7.2% | +158.7% | -166.0% | -11.8% |
| 3M | -1.0% | +182.1% | -183.1% | -6.6% |
| 6M | +11.5% | +151.8% | -140.3% | +5.7% |
| YTD | +14.3% | +393.6% | -379.2% | +4.7% |
| 1Y | +38.1% | +499.5% | -461.3% | +25.0% |
| 3Y | +55.0% | +29.3% | +25.7% | +47.9% |
| 5Y | +79.6% | -65.1% | +144.7% | +76.2% |
| All | +205.3% | +561.6% | -356.3% | +152.5% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling